Irbesartán/Hidroclorotiazida Pharma Combix

Irbesartan and Hydrochlorothiazide, the active ingredients in Irbesartán/Hidroclorotiazida Pharma Combix, are an angiotensin II receptor blocker and a thiazide diuretic presented as oral tablets for oral use. They are indicated for the treatment of hypertension in adult patients, helping to lower elevated blood pressure and reduce cardiovascular risk.

GNH USA supplies Irbesartán/Hidroclorotiazida Pharma Combix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Irbesartan/Hydrochlorothiazide is used in the management of hypertension, targeting elevated blood pressure and related cardiovascular stress.

- Essential hypertension: lowers systolic and diastolic blood pressure to target levels. - Controlled hypertension: assists patients who require additional blood pressure reduction beyond monotherapy. - Hypertension with fluid retention: combines diuretic action to reduce plasma volume and improve blood pressure control.

The combination may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness or light‑headedness. - Headache. - Increased urination. - Electrolyte disturbances (e.g., low potassium). - Fatigue. - Mild gastrointestinal upset.

Serious or Rare Side Effects: - Severe hypotension. - Acute kidney injury. - Hyperkalemia. - Angioedema. - Pancreatitis. - Severe allergic reactions (e.g., Stevens‑Johnson syndrome).

When prescribing Irbesartan/Hydrochlorothiazide, several precautions should be observed to ensure safe use. - Blood pressure monitoring: check BP regularly to avoid excessive lowering. - Renal function assessment: evaluate serum creatinine and eGFR before and during therapy. - Electrolyte surveillance: monitor potassium and sodium levels, especially in patients on other diuretics. - Use with caution in diabetes: may affect glucose control. - Avoid in severe hepatic impairment: limited data on safety. - Store at below 25°C: keep in the original pack, protect from moisture.

Irbesartan/Hydrochlorothiazide can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Aliskiren in diabetic patients: increased risk of renal impairment and hyperkalemia. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia. - ACE inhibitors or other ARBs: additive effects on potassium and renal function. - Lithium: increased lithium levels leading to toxicity. - NSAIDs (high dose): may reduce antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely): - Other antihypertensives (beta‑blockers, calcium channel blockers): may enhance blood pressure lowering. - CYP2C9 inhibitors (e.g., fluconazole, amiodarone): can increase irbesartan plasma concentrations. - Antidiabetic drugs: diuretic may affect glucose control. - Anticoagulants (warfarin): thiazide may increase INR. - High‑protein diets or supplements affecting electrolyte balance.